Remedium Lifecare Limited

BSE:539561 Stock Report

Market Cap: ₹2.2b

Remedium Lifecare Past Earnings Performance

Past criteria checks 3/6

Remedium Lifecare has been growing earnings at an average annual rate of 73.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 75.5% per year. Remedium Lifecare's return on equity is 52.5%, and it has net margins of 0.7%.

Key information

73.9%

Earnings growth rate

61.4%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate75.5%
Return on equity52.5%
Net Margin0.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Remedium Lifecare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:539561 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2433,454241210
30 Jun 2437,889291210
31 Mar 2440,417327210
31 Dec 2327,254528160
30 Sep 2310,53685180
30 Jun 237,41042180
31 Mar 235,09854160
31 Dec 224,76190140
30 Sep 225,05782120
30 Jun 224,6607160
31 Mar 225,04811110
31 Dec 215,2042590
30 Sep 213,2782070
30 Jun 212,279920
31 Mar 21900560
31 Dec 20349560
30 Sep 20221320
30 Jun 2029320
31 Mar 2029350
31 Dec 1923010
30 Jun 193000
31 Mar 192000
31 Dec 182010
30 Jun 183120
31 Mar 184010
31 Dec 179010
30 Sep 179010
30 Jun 1711010
31 Mar 1713010
31 Dec 1627020
30 Sep 1639020
30 Jun 1640010
31 Mar 1639010
31 Dec 1522010
30 Sep 1512010
30 Jun 1516310
31 Mar 1521610
31 Mar 1426010

Quality Earnings: 539561 has a high level of non-cash earnings.

Growing Profit Margin: 539561's current net profit margins (0.7%) are lower than last year (0.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 539561 has become profitable over the past 5 years, growing earnings by 73.9% per year.

Accelerating Growth: 539561's earnings growth over the past year (183.1%) exceeds its 5-year average (73.9% per year).

Earnings vs Industry: 539561 earnings growth over the past year (183.1%) exceeded the Pharmaceuticals industry 20%.


Return on Equity

High ROE: Whilst 539561's Return on Equity (52.52%) is outstanding, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies